ReviewVaccines2013
Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy.
Review in Vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- When the Liver Flares: Inflammatory and Immunometabolic Mechanisms Driving the Transition from MASLD to MASH.Inflammation · 2026Review
- Enhanced immunogenicity of the rabies virus glycoprotein fused to a dendritic cell-targeting peptide.Scientific reports · 2026Article
- Nanoparticle induction of antigen-presenting monocyte-derived dendritic cells relieves immunosuppression and inhibits metastasis.Cell biomaterials · 2026Article
- Identification of Shared Biomarkers in Chronic Kidney Disease and Diabetic Nephropathy Using Single-Cell Sequencing.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis.Frontiers in immunology · 2025Review
- Immunological mechanisms in Meniere's disease.Frontiers in immunology · 2025Review
- Immunologic Mechanisms of BCc1 Nanomedicine Synthesized by Nanochelating Technology in Breast Tumor-bearing Mice: Immunomodulation and Tumor Suppression.Anti-cancer agents in medicinal chemistry · 2024Article
- Anaesthesia in Veterinary Oncology: The Effects of Surgery, Volatile and Intravenous Anaesthetics on the Immune System and Tumour Spread.Animals : an open access journal from MDPI · 2023Review
- Dendritic Cell-Derived Artificial Microvesicles Inhibit RLSPharmaceutics · 2022Article
- The role of dendritic cells in the immunomodulation to implanted biomaterials.International journal of oral science · 2022Review
- Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.Journal for immunotherapy of cancer · 2022Article
- Article
- Dendritic Cells and Antiphospholipid Syndrome: An Updated Systematic Review.Life (Basel, Switzerland) · 2021Review
- Chemically SynthesizedFrontiers in pharmacology · 2021Article
- Differentiation and Regulation of TFrontiers in immunology · 2021Review
- Innate Immune Cells in Pressure Overload-Induced Cardiac Hypertrophy and Remodeling.Frontiers in cell and developmental biology · 2021Review
- A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- The Role of Dendritic Cells in TB and HIV Infection.Journal of clinical medicine · 2020Review
- A biomimetic yeast shell vaccine coated with layered double hydroxides induces a robust humoral and cellular immune response against tumors.Nanoscale advances · 2020Article
- Ex vivo pulsed dendritic cell vaccination against cancer.Acta pharmacologica Sinica · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The success of cellular immunotherapies against cancer requires the generation of activated CD4⁺ and CD8⁺ T-cells. The type of T-cell response generated (e.g., Th1 or Th2) will determine the efficacy of the therapy, and it is generally assumed that a type-1 response is needed for optimal cancer treatment. IL-17 producing T-cells (Th17/Tc17) play an important role in autoimmune diseases, but their function in cancer is more controversial. While some studies have shown a pro-cancerous role for IL-17, other studies have shown an anti-tumor function. The induction of polarized T-cell responses can be regulated by dendritic cells (DCs). DCs are key regulators of the immune system with the ability to affect both innate and adaptive immune responses. These properties have led many researchers to study the use of ex vivo manipulated DCs for the treatment of various diseases, such as cancer and autoimmune diseases. While Th1/Tc1 cells are traditionally used for their potent anti-tumor responses, mounting evidence suggests Th17/Tc17 cells should be utilized by themselves or for the induction of optimal Th1 responses. It is therefore important to understand the factors involved in the induction of both type-1 and type-17 T-cell responses by DCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.